If you or someone you love has been injured by Xarelto, you may be eligible to file a Xarelto blood thinner lawsuit. These cases may involve the manufacturer of the drug, Bayer Corporation, or Johnson & Johnson, two of the world’s largest pharmaceutical companies. These companies have unlimited resources, and you may be able to bring a claim against them for the injury that they caused.


The Mingo Xarelto lawsuit began in August 2017 in federal court in Mississippi. The woman, who suffered from severe GI bleeding after taking the drug for a month in 2015, said that the medication was to blame for her condition. Xarelto was prescribed for Mingo because she was worried about blood clotting after a hip surgery. During the trial, the jury deliberated for four hours before deciding the case.

Upon her admission, Ms. Mingo’s condition was aggravated, and she was treated in the ICU. During her treatment, she discontinued her Xarelto use and underwent transfusions of four units of packed red blood cells and two units of fresh frozen plasma. After she recovered, Dr. Stephen Keith performed an esophagogastroduodenoscopy, which revealed a six-millimeter oozing ulcer. During the surgery, he also placed a hemoclip to sever the blood flow and prevent it from leaking.


The Orr vs Xarelto blood thinner lawsuit is an important step in the investigation of this drug’s dangers. The pharmaceutical company, Johnson & Johnson, and its subsidiary Janssen Pharmaceuticals have settled over 25,000 lawsuits in U.S. courts. The Philadelphia CLC, which handles major litigation in Pennsylvania, has begun reviewing Xarelto cases. During this process, bellwether trials are used to gauge the value of similar lawsuits.

In the Orr vs Xarelto blood thinner lawsuit, plaintiffs’ attorneys argued that Xarelto was unreasonably dangerous. Xarelto is a blood thinner that carries a serious risk of irreversible, uncontrolled bleeding. Orr began taking Xarelto in February 2014 but suddenly became ill on April 24, 2015. She was taken by ambulance to the hospital and became nonresponsive. She died on May 4, 2015.


Bayer and Johnson & Johnson have settled a major Xarelto blood thinner lawsuit, citing the lack of merit in the claims. In addition, the settlement avoids the significant costs and distraction of ongoing litigation. Last month, the judge dismissed a separate lawsuit against the companies because the risks of Xarelto were known. The drug is Bayer’s top-selling drug, with nearly $4 billion in sales last year.

One of the two bellwether trials involving Xarelto was in a Pennsylvania state court. The plaintiff was prescribed Xarelto by her doctor to prevent strokes and irregular heartbeats. However, she developed severe gastrointestinal bleeding after taking the drug. She was ultimately hospitalized for a week, and she blamed her hospitalization on Xarelto. In addition to her Xarelto-related gastrointestinal bleeding, the plaintiff said that the drug companies failed to provide adequate warnings and instructions to consumers.

Johnson & Johnson

In the first bellwether case involving the Xarelto blood thinner, Johnson & Johnson won the case. Now, the company is defending itself in another lawsuit against the maker of the medication. The plaintiff, Sharyn Orr, died of a hemorrhagic stroke after taking Xarelto. Her death, a result of a brain hemorrhage, was entirely preventable. It appears that the drug makers intentionally concealed the risks of the drug.

In a recent court case, Bayer and Johnson & Johnson were found not liable in a multimillion-dollar Xarelto lawsuit. Plaintiff Lynn Hartman was taking the drug for irregular heart rhythms and suffered severe internal bleeding. She was taken off Xarelto after experiencing bleeding complications. In 2014, Hartman was hospitalized after suffering gastrointestinal bleeding from taking the drug. Bayer and J&J had co-developed the blockbuster drug. The jury ruled that the makers failed to disclose the risk of internal bleeding, despite the warning on the drug’s label.


The Defendants in the Xarelto blood thinner lawsuit are denying that the drug caused severe bleeding. Specifically, they are saying that the warnings for the drug are inadequate. The warnings for Xarelto were inadequate in that they did not warn patients of the risk of internal bleeding, even though they knew of this risk. In August 2017, a bellwether trial was held. This trial was filed by Dora Mingo, who suffered gastrointestinal bleeding after taking the drug for one month. Mingo had been prescribed Xarel prevent blood clots after an operation, but she developed bleeding after taking the drug for a month. The jury deliberated for four hours before deciding on the case.

The multidistrict litigation, which includes all Xarelto-related personal injury claims, will resolve all the cases filed in Louisiana. If you have retained a lawyer to file a Xarelto blood thinner lawsuit, you must file it by April 4, 2019. However, neither side has yet provided an estimate of how much compensation will be awarded. The payments will be significantly reduced if you file your lawsuit after Dec. 1, 2015, or March 1, 2016.

Leave a comment

Your email address will not be published. Required fields are marked *